CY1106794T1 - Θεραπεια μολυνσης απο μυκητα με πολυενιο ή με αντιμυκητιασικα αναστολεα της συνθασης της βητα γλουκανης σε συνδυασμο με αντισωματα αντι hsp90 - Google Patents
Θεραπεια μολυνσης απο μυκητα με πολυενιο ή με αντιμυκητιασικα αναστολεα της συνθασης της βητα γλουκανης σε συνδυασμο με αντισωματα αντι hsp90Info
- Publication number
- CY1106794T1 CY1106794T1 CY20071101053T CY071101053T CY1106794T1 CY 1106794 T1 CY1106794 T1 CY 1106794T1 CY 20071101053 T CY20071101053 T CY 20071101053T CY 071101053 T CY071101053 T CY 071101053T CY 1106794 T1 CY1106794 T1 CY 1106794T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fungal
- polyene
- treatment
- combination
- synthesis inhibitors
- Prior art date
Links
- SPMCUTIDVYCGCK-IIIGWGBSSA-N (2s,3r,4s,5r,6r)-2-[(2r,3r,4r,5s)-3,5-dihydroxy-2-(hydroxymethyl)oxan-4-yl]oxy-4-[(2s,3r,5s,6r)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-3,5-diol Chemical compound O[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)OC[C@@H]2O)O)O[C@H](CO)[C@H]1O SPMCUTIDVYCGCK-IIIGWGBSSA-N 0.000 title 1
- 229920002498 Beta-glucan Polymers 0.000 title 1
- 206010017533 Fungal infection Diseases 0.000 title 1
- 208000031888 Mycoses Diseases 0.000 title 1
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000004291 polyenes Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Η παρούσα εφεύρεση συνδέεται με καινοτόμες συνθέσεις και παρασκευάσματα που είναι αποτελεσματικοί αντιμυκητιασικοί παράγοντες και ένα καινοτόμο αντίσωμα που μπορεί να ενσωματωθεί στις συνθέσεις και στα παρασκευάσματα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0008305.5A GB0008305D0 (en) | 2000-04-06 | 2000-04-06 | Treatment of fungal infections |
PCT/GB2001/001195 WO2001076627A1 (en) | 2000-04-06 | 2001-03-20 | Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106794T1 true CY1106794T1 (el) | 2012-05-23 |
Family
ID=9889204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101053T CY1106794T1 (el) | 2000-04-06 | 2007-08-07 | Θεραπεια μολυνσης απο μυκητα με πολυενιο ή με αντιμυκητιασικα αναστολεα της συνθασης της βητα γλουκανης σε συνδυασμο με αντισωματα αντι hsp90 |
Country Status (19)
Country | Link |
---|---|
US (4) | US20030180285A1 (el) |
EP (4) | EP1852128A1 (el) |
JP (1) | JP2003530357A (el) |
CN (3) | CN1420786A (el) |
AT (1) | ATE364396T1 (el) |
AU (2) | AU2001240890B2 (el) |
BR (1) | BR0109846A (el) |
CA (1) | CA2401836A1 (el) |
CY (1) | CY1106794T1 (el) |
DE (1) | DE60128893T2 (el) |
DK (1) | DK1267925T3 (el) |
ES (1) | ES2287105T3 (el) |
GB (1) | GB0008305D0 (el) |
NO (1) | NO20024815L (el) |
NZ (1) | NZ520899A (el) |
PL (1) | PL358394A1 (el) |
PT (1) | PT1267925E (el) |
RU (1) | RU2262952C2 (el) |
WO (1) | WO2001076627A1 (el) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
US7959915B2 (en) | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
EP1457499A1 (en) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
GB0409077D0 (en) * | 2004-04-23 | 2004-05-26 | Neutec Pharma Plc | Treatment of fungal infections |
CA2572318A1 (en) | 2004-07-02 | 2006-01-12 | Neutec Pharma Plc | Treatment of cancer |
SG153877A1 (en) * | 2004-07-02 | 2009-07-29 | Neutec Pharma Plc | Treatment of cancer |
WO2006091459A2 (en) * | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
JP5154406B2 (ja) * | 2005-04-13 | 2013-02-27 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
GB0600168D0 (en) * | 2006-01-05 | 2006-02-15 | Neutec Pharma Plc | A therapeutic composition |
GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
WO2008091692A2 (en) * | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
WO2008116216A1 (en) * | 2007-03-22 | 2008-09-25 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for inhibiting cancer metastasis |
US20100113355A1 (en) * | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
WO2008132174A1 (en) * | 2007-04-27 | 2008-11-06 | Novartis Ag | An immunoglobulin composition |
US10457726B2 (en) | 2016-06-30 | 2019-10-29 | University Of Connecticut | Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof |
CN113845591B (zh) * | 2018-10-30 | 2023-10-31 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
CN111679069A (zh) * | 2019-12-31 | 2020-09-18 | 安徽中医药大学 | 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
GB2270076A (en) * | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
US6375955B1 (en) * | 1995-09-22 | 2002-04-23 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6365165B1 (en) * | 1995-09-22 | 2002-04-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
US5834592A (en) * | 1995-09-22 | 1998-11-10 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2000
- 2000-04-06 GB GBGB0008305.5A patent/GB0008305D0/en not_active Ceased
-
2001
- 2001-03-20 US US10/240,819 patent/US20030180285A1/en not_active Abandoned
- 2001-03-20 JP JP2001574143A patent/JP2003530357A/ja active Pending
- 2001-03-20 CN CN01807383A patent/CN1420786A/zh active Pending
- 2001-03-20 WO PCT/GB2001/001195 patent/WO2001076627A1/en active IP Right Grant
- 2001-03-20 AU AU2001240890A patent/AU2001240890B2/en not_active Ceased
- 2001-03-20 DE DE60128893T patent/DE60128893T2/de not_active Expired - Lifetime
- 2001-03-20 CA CA002401836A patent/CA2401836A1/en not_active Abandoned
- 2001-03-20 PT PT01911971T patent/PT1267925E/pt unknown
- 2001-03-20 RU RU2002129510/15A patent/RU2262952C2/ru not_active IP Right Cessation
- 2001-03-20 AT AT01911971T patent/ATE364396T1/de active
- 2001-03-20 EP EP07075462A patent/EP1852128A1/en not_active Withdrawn
- 2001-03-20 DK DK01911971T patent/DK1267925T3/da active
- 2001-03-20 CN CN200910167220A patent/CN101683525A/zh active Pending
- 2001-03-20 AU AU4089001A patent/AU4089001A/xx active Pending
- 2001-03-20 BR BR0109846-2A patent/BR0109846A/pt not_active IP Right Cessation
- 2001-03-20 PL PL01358394A patent/PL358394A1/xx not_active Application Discontinuation
- 2001-03-20 EP EP07075857A patent/EP2011512A1/en not_active Withdrawn
- 2001-03-20 ES ES01911971T patent/ES2287105T3/es not_active Expired - Lifetime
- 2001-03-20 NZ NZ520899A patent/NZ520899A/en not_active IP Right Cessation
- 2001-03-20 CN CNA2007101126651A patent/CN101095952A/zh active Pending
- 2001-03-20 EP EP01911971A patent/EP1267925B8/en not_active Expired - Lifetime
- 2001-03-20 EP EP07075188A patent/EP1818062A3/en not_active Withdrawn
-
2002
- 2002-10-04 NO NO20024815A patent/NO20024815L/no not_active Application Discontinuation
-
2007
- 2007-08-07 CY CY20071101053T patent/CY1106794T1/el unknown
- 2007-11-14 US US11/984,177 patent/US20100285029A1/en not_active Abandoned
-
2008
- 2008-03-20 US US12/076,643 patent/US20080193459A1/en not_active Abandoned
- 2008-03-21 US US12/076,705 patent/US20080181884A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106794T1 (el) | Θεραπεια μολυνσης απο μυκητα με πολυενιο ή με αντιμυκητιασικα αναστολεα της συνθασης της βητα γλουκανης σε συνδυασμο με αντισωματα αντι hsp90 | |
CY2015057I2 (el) | Μονοκλωνικα αντισωματα ανθρωπου εναντι της πρωτεϊνης προγραμματισμενου θανατου (pd-1) και μεθοδοι αγωγης εναντι του καρκινου χρησιμοποιωντας αντισωματα αντι-pd-1 μεμονωμενα 'h σε συνδυασμο με αλλους ανοσοθεραπευτικους παραγοντες | |
CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
CY1105078T1 (el) | Ανταγωνιστες τεκ | |
CY1109730T1 (el) | Μιμητικα θρομβοποιητινης | |
CY1115730T1 (el) | Θεραπευτικοι επιτοποι και χρησεις αυτων | |
BR0312692A (pt) | anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer | |
CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
CR7786A (es) | Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos | |
CY1107503T1 (el) | Αντιβιοτικα διπλης δρασης | |
BR0114646A (pt) | anticorpos anti-lt-beta-r humanizados | |
CY1106532T1 (el) | Ετερολογος εκφραση των πρωτεϊνων της neisseria | |
ECSP066294A (es) | Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo | |
CY1111872T1 (el) | Συνθεσεις υποτασικου λιπιδιου (προσταγλανδινης) και τιμολολης - σχετικες μεθοδοι χρησης | |
CY1108211T1 (el) | Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη | |
UY26807A1 (es) | Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos | |
NO20025302D0 (no) | Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler | |
CY1110669T1 (el) | Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης | |
CY1105892T1 (el) | Θepαπεια του ξανθωματος με παραγωγα αζετιδινονης ως αναστολεις απορροφησης στepολης | |
CY1106074T1 (el) | Πεπτιδια με αντιαγγειογονο δραση | |
CY1105008T1 (el) | Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης | |
DE60042369D1 (de) | Chemisch programmierbare immunität | |
DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
CY1107485T1 (el) | 3-θειομεθυλπυραζoλες ως παρασιτοκτoνα | |
CY1111567T1 (el) | Ενδιαμεσα διβενζο (b,f) αζεπινης |